Related Experiment Video
Updated: Aug 15, 2026
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
[Comparative characteristics of a test system for detecting antibodies to hepatitis C virus]
Insights
Comparing enzyme immunoassay (EIA) kits for hepatitis C virus (HCV) antibody detection revealed no single ideal kit. Sensitivity is crucial for blood donor screening, while specificity is vital for diagnostics.
Area of Science:
- Clinical Virology
- Immunodiagnostics
- Public Health
Background:
- Hepatitis C virus (HCV) poses a significant global health challenge.
- Accurate antibody detection is critical for blood safety and patient diagnosis.
- Enzyme immunoassay (EIA) kits are widely used for HCV screening.
Purpose of the Study:
- To compare the sensitivity and specificity of various EIA kits for detecting anti-HCV antibodies.
- To evaluate the performance of different EIA kits in a donor blood screening context.
- To determine optimal strategies for HCV screening and diagnosis based on kit performance.
Main Methods:
- Screening of 3308 blood donors using Akvapast immunodiagnosticum (lot 12).
- Confirmatory testing of anti-HCV positive sera with Akvapast (other lots), Hepascan, Blot-0.5, and immunoComb.
- Comparative analysis of diagnostic performance metrics (sensitivity, specificity).
Main Results:
- Anti-HCV antibodies were detected in 1.3% (43/3308) of donors.
- No single EIA kit demonstrated ideal sensitivity and specificity for anti-HCV antibody detection.
- Performance varied across different kits and lots.
Conclusions:
- Highly sensitive EIA kits are recommended for mass screening of blood donors.
- Highly specific EIA kits are advisable for in-depth diagnosis and monitoring.
- A robust system for reference and expert diagnosis of hepatitis C is still needed.
Abstract:
The sensitivities and specificities of enzyme immunoassay (EIA) kits for the detection of antibodies to hepatitis C virus (HCV) were compared in donor blood screening. A total of 3308 donors were examined using Akvapast immunodiagnosticum (St. Petersburg), lot 12. Anti-HCV antibodies were detected in 43 (1.3%) subjects. Blood sera of these donors were additionally investigated using other lots of Akvapast, Hepascan (Bioservice, Moscow), Blot-0.5 (Bioservice, Moscow), and immunoComb (France). The studies demonstrated that none of the agents used can be acknowledged as ideally sensitive and specific for the detection of anti-HCV antibodies. Maximally sensitive diagnostic kits should be preferred for the screening of donors of blood components and for other mass surveys. Highly-specific test systems are advisable for profound examinations and diagnostic monitoring. The creation of a system of reference and expert diagnosis of hepatitis C remains a pressing task.
